Navigation Links
Angiotech To Commence Cash Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014
Date:7/7/2008

lowing: the inability to consummate the transaction described in this press release or that the transaction will not provide the anticipated benefits described in this press release; general economic and business conditions, both nationally and in the regions in which we operate; market demand; technological changes that could impact our existing products or our ability to develop and commercialize future products; competition; existing governmental regulations and changes in, or the failure to comply with, governmental regulations; adverse results or unexpected delays in pre-clinical and clinical product development processes; adverse findings related to the safety and/or efficacy of our products or products sold by our partners; decisions, and the timing of decisions, made by health regulatory agencies regarding approval of our technology and products; the requirement for substantial funding to conduct research and development and to expand manufacturing and commercialization activities or consummate acquisitions; and any other factors that may affect performance. In addition, our business is subject to certain operating risks that may cause the actual results expressed or implied by the forward-looking statements in this press release to differ materially from our actual results. These operating risks include: our ability to attract and retain qualified personnel; our ability to successfully complete pre-clinical and clinical development of our products; changes in business strategy or development plans; our failure to obtain patent protection for discoveries; loss of patent protection resulting from third-party challenges to our patents; commercialization limitations imposed by patents owned or controlled by third parties; our ability to obtain rights to technology from licensors; liability for patent claims and other claims asserted against us; our ability to obtain and enforce timely patent and other intellectual property protection for our technology and prod
'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Angiotech announces market launch of Quill(TM) SRS MONODERM(TM)
2. Angiotechs corporate partner, Cook Medical, announces positive interim results for its Zilver(R) PTX(TM) clinical study
3. Angiotech announces completion of Bio-Seal(TM) clinical trial enrolment
4. Angiotech appoints Hank McKinnell to its Board of Directors
5. Angiotech to participate in Bank of America Health Care Conference
6. Angiotech Expands Quill(TM) SRS product offering receiving FDA 510(k) approval for smaller size diameters of Quill(TM) SRS PDO
7. Angiotech elects to suspend Vascular Wrap(TM) pivotal clinical trials
8. Angiotechs Corporate Partner, Boston Scientific, Reports Canadian Approval for TAXUS(R) Liberte(R) Stent System
9. Angiotechs novel 5-FU Central Venous Catheter receives FDA 510(k) clearance
10. Angiotech announces director resignation
11. Angiotech announces commercial launch of Cook Medicals Zilver(R) PTX(TM) drug-eluting peripheral stent in New Zealand
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Women in the West African ... additional family planning option. Sayana® Press has the ... levels of the health system and in communities ... used contraceptive—Pfizer’s Depo-Provera® (depot medroxyprogesterone acetate)—with the BD ... first of four African countries expected to begin ...
(Date:7/10/2014)... Unraveling life’s mysteries can intrigue, amaze, and ... purchased a DNA test to unravel the ... a lifetime of memories, sharing, and closeness. In fact, ... genuinely brought the family closer together. , Recently, ... history and prior to taking the genetic ancestry ...
(Date:7/10/2014)... CROWN POINT, Ind. , July 10, ... recently expanded its use of capnography for ... a growing group of healthcare leaders in ... Capnography measures how effectively patients are breathing ... respiratory depression occurs. By measuring the amount ...
(Date:7/10/2014)... OAKS, Calif., July 10, 2014   Ceres, Inc ... and seed company, announced today financial results for the ... update on its business. Ceres reported that ... in product performance this growing season in Brazil, which ... affected the company,s sorghum evaluation areas for part of ...
Breaking Biology Technology:Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9
... $0.64 - $0.67 from Prior Range of ... $0.47 - $0.53,Reaffirms Adjusted EPS Guidance of $0.90 - $1.10 for 2009 and ... ... its financial results for the three and nine months ended,Sept. 30, 2008., Financial Highlights, ...
... Vanda Pharmaceuticals,Inc. (Nasdaq: VNDA ), a biopharmaceutical ... product candidates for central,nervous system disorders, today announced ... September 30, 2008., Vanda reported research and ... of $3.8 million, compared to $5.5 million in ...
... GmbH, the leading,European manufacturer of cardiac occlusion devices, today ... Hague, Holland, against AGA Medical Inc.,regarding non-infringement of the ... patent court in The Hague stated that the disputed ... 0808138 (equivalent of,German patent DE 695 34 505.2) held ...
Cached Biology Technology:Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 2Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 3Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 4Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 5Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 6Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 7Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 8Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 9Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 10Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 11Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 12Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 13Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008 14Vanda Pharmaceuticals Reports Third Quarter 2008 Results 2Vanda Pharmaceuticals Reports Third Quarter 2008 Results 3Vanda Pharmaceuticals Reports Third Quarter 2008 Results 4Vanda Pharmaceuticals Reports Third Quarter 2008 Results 5Vanda Pharmaceuticals Reports Third Quarter 2008 Results 6Vanda Pharmaceuticals Reports Third Quarter 2008 Results 7Vanda Pharmaceuticals Reports Third Quarter 2008 Results 8Vanda Pharmaceuticals Reports Third Quarter 2008 Results 9Vanda Pharmaceuticals Reports Third Quarter 2008 Results 10Occlutech Obtains Favourable Court Ruling in Patent Litigation in The Hague Against AGA Medical 2
(Date:7/10/2014)... , July 2, 2014  Unisys Corporation,s (NYSE: ... , Unisys Nederland N.V., today announced that it has been ... implement and manage a new Basic Provision Biometrics solution for ... Unisys won the contract with a solution based on ... software. The term of the contract is up to seven ...
(Date:7/10/2014)... 2, 2014 NXT-ID, Inc., (OTCQB: NXTD) a biometric authentication company ... Gino Pereira was interviewed on July 1 st ... Tampa Florida . Mr. Pereira discusses the company,s next ... and how the Wocket™ aims to replace a traditional ... Cedric Harris tells Gino he has never heard ...
(Date:7/10/2014)... Research and Markets ( http://www.researchandmarkets.com/research/h7h8lq/gesture ) ... Gesture Recognition & Touch-Less Sensing (2D, 3D, Ultrasonic, ... report to their offering ... Touch-Less Sensing Market to Grow Exponentially. Touch-less sensing ... the companies were unable to leverage this technology ...
Breaking Biology News(10 mins):Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 2Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 3Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 2Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 3Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 4Global Gesture Recognition & Touch-Less Sensing (2D, 3D, Ultrasonic, IR, Capacitive) Market - Forecasts to 2020 2
... western Pacific Ocean may be losing their last foothold ... a paper published today in the scientific journal ... Researchers from the State University of Papua Indonesia, ... World Wildlife Fund Indonesia released a report today documenting ...
... articles cover wind erosion and sediment traps in the Qaidam ... Forest, USA; a forearc sliver in Costa Rica; Quebec,s St. ... Ries Crater Lake, Germany; bending and buckling mountain belts; a ... and the evolution of the ancient Montana landscape. ...
... The Association for Research in Vision and Ophthalmology 2013 ... including two Nobel laureates, during the organization,s five-day conference, ... this year, the ARVO/Alcon Keynote Series will include Oliver ... DPhil. Smithies, of the University of North Carolina ...
Cached Biology News:New study shows continued decline in the last remaining stronghold for leatherback sea turtles 2Kauai, the Petrified Forest, Costa Rica, and more: New GSA Bulletin articles now online 2Kauai, the Petrified Forest, Costa Rica, and more: New GSA Bulletin articles now online 3Kauai, the Petrified Forest, Costa Rica, and more: New GSA Bulletin articles now online 4Kauai, the Petrified Forest, Costa Rica, and more: New GSA Bulletin articles now online 5Kauai, the Petrified Forest, Costa Rica, and more: New GSA Bulletin articles now online 6Kauai, the Petrified Forest, Costa Rica, and more: New GSA Bulletin articles now online 7Kauai, the Petrified Forest, Costa Rica, and more: New GSA Bulletin articles now online 8Kauai, the Petrified Forest, Costa Rica, and more: New GSA Bulletin articles now online 93 distinguished keynote speakers to present during ARVO 2013 Annual Meeting 2
... Well Plate Sterile with ... range of 384-well plates ... screening and research. These ... and are suitable for ...
Request Info...
... to Cytokeratin 5 / 6 Cytokeratin ... weight, basic type of cytokeratin expressed in ... layers of stratified epithelia as well as ... cells and mesothelioma. Cytokeratin 6 (56 kD) ...
Bovine Coronary Artery Endothelial Cells (BCAEC) (>500,000 cells)...
Biology Products: